Eisai Co., Ltd. (OTCMKTS:ESALY) – Equities researchers at Jefferies Financial Group upped their FY2022 earnings per share estimates for Eisai in a note issued to investors on Wednesday, January 12th. Jefferies Financial Group analyst S. Barker now expects that the company will post earnings per share of $1.84 for the year, up from their prior forecast of $1.75. Jefferies Financial Group also issued estimates for Eisai’s FY2023 earnings at $1.46 EPS, FY2024 earnings at $2.29 EPS, FY2025 earnings at $3.84 EPS and FY2026 earnings at $1.86 EPS.
A number of other equities analysts have also recently commented on ESALY. Citigroup cut Eisai from a “buy” rating to a “neutral” rating in a report on Thursday. Zacks Investment Research raised Eisai from a “sell” rating to a “hold” rating in a report on Tuesday, December 21st.
Eisai (OTCMKTS:ESALY) last released its earnings results on Monday, November 1st. The company reported $0.13 earnings per share for the quarter. Eisai had a return on equity of 8.50% and a net margin of 9.00%. The firm had revenue of $1.48 billion during the quarter.
Eisai Co, Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.